Non-exclusive rebate agreement for Infliximab (ATC L04AB02)
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab (ATC-Code nach WHO: L04AB02)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No minimum purchase volumes and actual demand unknown; may lead to low or no revenue.
The buyer may terminate the Open-House if an exclusive rebate agreement is concluded, typically 8-12 months after publi...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Apr 30, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Establish non-exclusive rebate agreements for Infliximab (ATC L04AB02) for intravenous infusion
- Supply of pharmaceutical products to AOK PLUS insured persons in Saxony and Thuringia
Show full summary
This is an Open-House model for non-exclusive rebate agreements under §130a(8) SGB V for the drug Infliximab (ATC L04AB02) for intravenous infusion. The buyer is AOK PLUS (Saxony and Thuringia). The procedure is open to all pharmaceutical companies meeting participation requirements. No minimum purchase volumes are guaranteed; actual demand is unknown. The contract runs until 30 April 2027. The notice clarifies that this is not a public procurement under EU Directive 2014/24/EU but is published for transparency. No estimated value is provided. Submission is electronic via DTVP, with confidentiality obligations. The first submission deadline is 5 May 2025; later deadlines are provided in separate documents.
Risks
No minimum purchase volumes and actual demand unknown; may lead to low or no revenue.
The buyer may terminate the Open-House if an exclusive rebate agreement is concluded, typically 8-12 months after publi...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company within the meaning of §4(18) AMG
Eligibility
- Must submit a declaration on exclusion grounds (§§123,124 GWB)
Administrative
- Must submit a declaration on EU Russia sanctions (Art. 5k of Regulation (EU) 2022/576)
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive rebate agreement for Infliximab (ATC L04AB02)
Open-House model for non-exclusive rebate agreements for the active substance Infliximab (intravenous infusion). All interested pharmaceutical companies can participate if they meet the conditions. No negotiation or exclusivity. Volume unknown.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Infliximab (ATC-Code nach WHO: L04AB02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 24 Mar 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 189631-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No minimum purchase volumes and actual demand unknown; may lead to low or no revenue.
The buyer may terminate the Open-House if an exclusive rebate agreement is concluded, typically 8-12 months after publi...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications